Aldebaran Capital LLC Has $899,000 Holdings in ESSA Pharma Inc. (NASDAQ:EPIX)

Key Points

• Aldebaran Capital LLC increased its holdings in ESSA Pharma Inc. by 43.2% in Q1, now owning 569,294 shares worth approximately $899,000.
• ESSA Pharma reported a Q2 EPS of ($0.09), surpassing estimates and with analysts predicting an average EPS of ($0.42) for the current year.
• Institutional investors own about 75.12% of ESSA Pharma, indicating strong interest from hedge funds in the company.

Aldebaran Capital LLC grew its position in ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI by 43.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 569,294 shares of the company's stock after purchasing an additional 171,771 shares during the period. ESSA Pharma comprises about 0.9% of Aldebaran Capital LLC's holdings, making the stock its 23rd largest position. Aldebaran Capital LLC owned approximately 1.28% of ESSA Pharma worth $899,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of EPIX. Tang Capital Management LLC acquired a new position in ESSA Pharma in the 4th quarter worth about $7,697,000. Altium Capital Management LLC bought a new stake in shares of ESSA Pharma during the 4th quarter worth about $2,556,000. Bank of America Corp DE boosted its stake in shares of ESSA Pharma by 10,153,775.0% during the 4th quarter. Bank of America Corp DE now owns 812,310 shares of the company's stock worth $1,454,000 after acquiring an additional 812,302 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of ESSA Pharma during the 4th quarter worth about $378,000. Finally, Marshall Wace LLP bought a new stake in shares of ESSA Pharma during the 4th quarter worth about $324,000. 75.12% of the stock is owned by institutional investors and hedge funds.

ESSA Pharma Stock Performance

EPIX opened at $1.93 on Friday. The company has a market cap of $85.67 million, a PE ratio of -3.45 and a beta of 1.55. The stock has a 50-day moving average of $1.80 and a 200-day moving average of $1.71. ESSA Pharma Inc. has a 52-week low of $1.40 and a 52-week high of $7.88.

ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.08. On average, research analysts predict that ESSA Pharma Inc. will post -0.42 earnings per share for the current year.

ESSA Pharma Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.